Chengdu Huasun Group Inc Ltd

Huashen Technology disclosed its 2026 interim report, posting net profit attributable to shareholders of the listed company of 6.11 million yuan in the first half, compared with a loss of 54.84 million yuan in the same period last year, swinging to profit. The company achieved total operating revenue of 233 million yuan, down 20.16 percent year on year, with basic earnings per share of 0.0098 yuan. The decline in operating revenue was mainly because former subsidiary Tibet Kangyu has no longer been included in the consolidation scope since September 2025.

Huashen Technology disclosed its earnings forecast, expecting a net profit attributable to the parent company of 4.8 million to 7.1 million yuan for the first half of 2026, compared with a loss of 54.844 million yuan in the same period last year, achieving a year-on-year turnaround. Deducted non-recurring net profit is expected to be 4.4 million to 6.5 million yuan, compared with a loss of 54.6253 million yuan in the same period last year. Basic earnings per share are expected to be between 0.0077 yuan and 0.0114 yuan. The company stated that the change in performance is mainly due to its continued focus on the core pharmaceutical business, in-depth exploration of the clinical value of products, active expansion of incremental markets outside hospitals, and simultaneous dynamic optimization of resources and expense investment, improvement of the cost control system, and enhancement of market operation efficiency and business quality.